AletaBiotherapeutics is a cutting-edge brand specializing in biologic therapies for cancer patients. Their innovative engager proteins, known as Aleta CAR T Engagers (CTEs), have the ability to transform cancer cells, allowing CAR-T cells to effectively kill every targeted tumor cell. Aleta's CTEs are specifically designed to address the needs of patients at risk of lymphoma or myeloma relapse, providing them with a simple, potent, off-the-shelf solution.

In addition to their advancements in B cell lymphoma, B cell leukemia, and multiple myeloma, Aleta's technology aims to extend CAR T cell therapies to treat non-B cell cancers, including acute myeloid leukemia (AML), breast cancer, gastric cancer, and pediatric brain tumors. Aleta's lead development program, ALETA-001, has garnered significant attention and support, receiving funding from Cancer Research UK and an Innovation Passport. This program focuses on patients experiencing relapse following treatment with anti-CD19 CAR T cell therapy.

With a team led by renowned industry experts and a comprehensive portfolio of therapies in the pipeline, AletaBiotherapeutics is at the forefront of transforming the landscape of cancer treatment